Menu
Not yet recruiting NCT06833775

Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

Observational Esophageal Cancer Neoadjuvant Therapy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Esophageal Cancer, Neoadjuvant Therapy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as well as clinical indicators collected before and after neoadjuvant treatment.

Primary outcome measures

  • CT and multimodal MRI in prediction of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer [Time frame: March 2025 - January 2030]

Eligibility criteria

Inclusion criteria

  • Consecutive patients with histopathological diagnosis of esophageal cancer.
  • Patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy.
  • All patients underwent CT and multimodal MRI examinations before and after neoadjuvant therapy.
  • The preoperative clinical data and postoperative pathological data are complete.

Exclusion criteria

  • Patients with other primary malignant tumors or previous anti-tumor treatment.
  • CT and MRI images with poor quality.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06833775 · 2024-621

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗